Camson Bio Technologies Limited reported unaudited standalone earnings results for the third quarter and nine months ended December 31, 2016. For the quarter, on standalone basis, the company reported total income from operations of INR 53.855 million compared to INR 45.455 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 20.271 million compared to INR 84.950 million a year ago. Loss from ordinary activities before tax was INR 39.046 million compared to of INR 96.953 million a year ago. Net loss for the period was INR 35.133 million or INR 1.17 per diluted share before and after extraordinary items compared to of INR 101.391 million or INR 3.38 per diluted share and after extraordinary items a year ago. For the nine months, on standalone basis, the company reported total income from operations of INR 96.267 million compared to INR 310.378 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 130.631 million compared to INR 80.535 million a year ago. Loss from ordinary activities before tax was INR 159.553 million compared to INR 101.366 million a year ago. Net loss for the period was INR 158.990 million or INR 5.30 per diluted share before and after extraordinary items compared to INR 108.196 million or INR 3.61 per diluted share before and after extraordinary items a year ago.